Pregabalin
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Pregabalin: From Neuropathic Pain to Tendinitis
One-Sentence Summary
Pregabalin is an α2δ (alpha-2-delta) voltage-gated calcium channel ligand historically used for neuropathic pain and as adjunctive therapy for partial epilepsy, with additional off-label use in generalized anxiety disorder and fibromyalgia. The TxGNN model predicts it may be effective for Tendinitis, but this direction is currently supported by 0 clinical trials and only 6 tangentially related publications — mostly on post-surgical opioid-sparing analgesia rather than tendinitis treatment itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the evidence pack (no TFDA/DrugBank license text available); literature (PMID 30001248) indicates established use for neuropathic pain and adjunctive partial-epilepsy treatment |
| Predicted New Indication | Tendinitis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L4 |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data from DrugBank is not available (flagged as a High-severity data gap). Based on what is documented in the supporting literature and the model's own rationale, pregabalin acts as a ligand of the α2δ subunit of voltage-gated calcium channels, producing central antinociceptive and anti-hyperalgesic effects. Clinically, this mechanism has been used to reduce opioid consumption after arthroscopic shoulder (rotator cuff/tendon) surgery.
However, the mechanistic link to tendinitis itself is weak. Tendinitis is fundamentally an inflammatory/degenerative condition of tendon tissue, whereas pregabalin's action is centered on central pain sensitization rather than local inflammation, collagen repair, or tendon healing. The supporting literature largely describes pregabalin as a perioperative analgesic adjunct after tendon surgery (e.g., rotator cuff repair) — not as a treatment for tendinitis pathology or its resolution. As the evidence pack's own rationale states, there is "no direct correspondence" between pregabalin's mechanism and the inflammatory pathology of tendinitis; the prediction appears to arise from co-occurrence in the literature (pain management around tendon procedures) rather than a disease-modifying rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32839073 | 2021 | RCT | J Orthop Sci | Retrospective cohort evaluating analgesic efficacy and opioid-sparing effect of pregabalin after arthroscopic rotator cuff (tendon) repair surgery |
| 34052386 | 2022 | RCT | Arthroscopy | Perioperative oral pregabalin produced pain scores comparable to interscalene brachial plexus block after arthroscopic rotator cuff repair |
| 40818536 | 2025 | Review/Editorial | Arthroscopy | Editorial on piriformis syndrome diagnosis and surgical release of the piriformis tendon; not focused on pregabalin efficacy |
| 41017607 | 2025 | Case Report | Praxis | Case of fluoroquinolone-associated disability including tendinopathy after ciprofloxacin; pregabalin not the subject drug |
| 37051935 | 2023 | Case Report | Pain Practice | Case of posterior femoral cutaneous nerve impingement from hamstring tendonitis after marathon running |
| 39703364 | 2024 | Preclinical | Adv Pharmacol Pharm Sci | Rat study of a plant extract (not pregabalin) attenuating vincristine-induced peripheral neuropathy; only tangential relevance |
Note: none of the above studies directly evaluate pregabalin as a treatment for tendinitis; relevance is indirect (perioperative pain control around tendon surgery or unrelated tendon case reports).
Taiwan Market Information
Pregabalin is currently not marketed in Taiwan under this evidence pack (0 authorizations, no license records available).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are not yet available in this evidence pack; TFDA label retrieval is flagged as a Blocking data gap — DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials directly test pregabalin for tendinitis, and the supporting literature addresses perioperative opioid-sparing analgesia after tendon surgery rather than tendinitis treatment or resolution. The proposed mechanism (central calcium-channel modulation of pain sensitization) does not clearly address the underlying inflammatory/degenerative pathology of tendinitis, so the evidence level remains L4 (mechanistic/indirect only).
To proceed, the following is needed:
- TFDA label data (warnings/contraindications) — currently Blocking (DG001)
- Confirmed mechanism of action from DrugBank (DG002)
- A prospective study designed to evaluate pregabalin's effect on tendinitis pain/healing specifically, rather than post-surgical analgesia as a surrogate
- Reassessment of the TxGNN prediction rationale to rule out confounding from co-occurrence in perioperative pain literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.